Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) exists to find cures and ensure access to the best available treatments for blood cancer patients. LLS is the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. LLS has chapters throughout the country and in Canada.

Latest from Leukemia & Lymphoma Society

Third COVID-19 Vaccine Dose in Blood Cancers May Boost Antibody Production

October 13, 2021

Article

Patients with blood cancers may respond differently to doses of the COVID-19 vaccines based on the treatment they’re receiving, for example.

Join Our Community

September 16, 2021

Article

LLS Community is an online gathering place for patients, caregivers and healthcare professionals to share experiences and provide support.

New Study Shows Most Blood Cancer Patients Benefit from an Additional COVID-19 Vaccine Dose

September 15, 2021

Article

Immune suppressing treatments — an essential component of many patients' cancer care — can blunt vaccine immune response.

FDA Approves Brukinsa for Marginal Zone Lymphoma Treatment

September 15, 2021

Article

Patients with relapsed/refractory, pretreated marginal zone lymphoma are now eligible for treatment with Brukinsa.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26, 2021

Article

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Why the COVID-19 Vaccine is Important for Patients with Blood Cancers

April 27, 2021

Video

Patients with blood cancers are at a much higher risk of complications if they contract COVID-19, says an expert from the Leukemia & Lymphoma Society (LLS).